Lyell Immunopharma Inc (LYEL) — Financial Flexibility Index
Lyell Immunopharma Inc (LYEL) has a Financial Flexibility Index of -0.35x as of December 2025. Free cash flow of $-31.88 Million (operating CF $-32.25 Million minus capex $366.00K) represents 0% of total liabilities ($91.85 Million). Also explore Lyell Immunopharma Inc (LYEL) equity growth momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Lyell Immunopharma Inc Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for Lyell Immunopharma Inc across 7 annual periods. Check how strategically is Lyell Immunopharma Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Lyell Immunopharma Inc (2019–2025)
Year-by-year free cash flow to debt coverage for Lyell Immunopharma Inc. For the full company profile including market capitalisation, see market value of Lyell Immunopharma Inc.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.62x | $-149.24 Million | $-150.02 Million | $91.85 Million | ▼ -8.4% |
| 2024 | -1.50x | $-161.93 Million | $-162.39 Million | $108.03 Million | ▲ +11.5% |
| 2023 | -1.69x | $-161.01 Million | $-163.69 Million | $95.08 Million | ▼ -21.6% |
| 2022 | -1.39x | $-145.28 Million | $-169.56 Million | $104.31 Million | ▼ -353.1% |
| 2021 | -0.31x | $-60.74 Million | $-126.25 Million | $197.62 Million | ▲ +46.7% |
| 2020 | -0.58x | $-109.39 Million | $-160.87 Million | $189.84 Million | ▼ -253.2% |
| 2019 | 0.38x | $55.52 Million | $39.47 Million | $147.58 Million | — |